Skip to content
DataLookout
Menu

NCT06702995

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 1 year 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Jul 13, 2027
    • Eligibility criteria expanded, about 40 words
    • Primary endpoints: details revised at 2 of 3 entries
    • Secondary endpoints: details revised at 7 of 12 entries
  2. Minor Trial status: Enrolling by Invitation to Recruiting
    • Site details revised at 2 of 2 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Ph Ib/IIa: Overall safety profile including adverse events
Timeframe: Baseline up to approximately 2 years
Ph Ib/IIa: Recommended phase 2 doses (RP2D) of XNW5004 in combination with enzalutamide
Timeframe: Approximately 6 months
Preliminary efficacy determination as evaluated by disease specific response criteria
Timeframe: Baseline until disease progression or death or through study completion (approximately 2 years)

Secondary (9)

Ph Ib/IIa: Pharmacokinetic Parameters
Ph Ib: Pharmacodynamic Parameters
Overall Response Rate (ORR)
Disease Control Rate (DCR)
Evaluate overall survival
Show 4 moreShow less
Proportion of patients with a PSA response at week 12
Prostate-specific Antigen 50 (PSA50) Response
Time to first symptomatic skeletal event (SSE)
Ph IIb:Overall safety profile including adverse events

Arms and interventions

Phase IbExperimental

Participants with mCRPC will receive XNW5004 at escalating dose levels in combination with enzalutamide.

Phase IIaExperimental

Participants with mCRPC will receive XNW5004 in combination with enzalutamide.

Phase IIbExperimental

Participants with mCRPC will receive XNW5004 in combination with enzalutamide or enzalutamide alone

Drugs: XNW5004, enzalutamide

Sites

2 sites in 1 country